Literature DB >> 19200816

Changes in the evolution of meningococcal disease, 2001-2008, Catalonia (Spain).

Ana I Martínez1, Angela Dominguez, Manuel Oviedo, Sofia Minguell, Josep M Jansa, Gemma Codina, Julio A Vazquez.   

Abstract

Reported cases of meningococcal disease between 1997 and 2008 were analyzed to determine the evolution after the introduction of a conjugated vaccine. In <6 years, the incidence rate of serogroup C fell from 7.6 to 0.6 per 100,000 persons/year in the periods before (1997-2000) and after (2001-2007) the introduction of the conjugate vaccine. In serogroup B, the reduction was from 15.4 to 11.1. In <20 years case-fatality-rate increased only in serogroup B (3% and 7.4%, p=0.026). Serosubtype P1.15 was the most frequent in serogroup B (31%), mainly associated with serotype 4 (80%), and in serogroup C subtype P1.5 (36%), with serosubtype 2a (86%). Exhaustive surveillance of circulating meningococcal strains is essential.

Entities:  

Mesh:

Year:  2009        PMID: 19200816     DOI: 10.1016/j.vaccine.2009.01.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.

Authors:  Maria Grazia Pascucci; Valentina Di Gregori; Gabriella Frasca; Paola Rucci; Alba Carola Finarelli; Laura Moschella; Bianca Maria Borrini; Francesca Cavrini; Giovanna Liguori; Vittorio Sambri; Paolo Bonanni; Maria Pia Fantini
Journal:  Hum Vaccin Immunother       Date:  2013-12-30       Impact factor: 3.452

2.  Meningococcal disease in children in Merseyside, England: a 31 year descriptive study.

Authors:  Michelle C Stanton; David Taylor-Robinson; David Harris; Fauzia Paize; Nick Makwana; Scott J Hackett; Paul B Baines; F Andrew I Riordan; Omnia Marzouk; Alistair P J Thomson; Peter J Diggle; C Anthony Hart; Enitan D Carrol
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

3.  Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.

Authors:  Myint Tin Tin Htar; Sally Jackson; Paul Balmer; Lidia Cristina Serra; Andrew Vyse; Mary Slack; Margarita Riera-Montes; David L Swerdlow; Jamie Findlow
Journal:  BMC Public Health       Date:  2020-12-09       Impact factor: 3.295

4.  The spectrum of acute bacterial meningitis in elderly patients.

Authors:  Pere Domingo; Virginia Pomar; Natividad de Benito; Pere Coll
Journal:  BMC Infect Dis       Date:  2013-02-27       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.